GOT2抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-7: 293T cells, Hela cells, Human fetal liver tissue, mouse spleen tissue, Mouse heart tissue, human fetal brain tissue, hepatocellular carcinoma tissue, Primary antibody: P01420(GOT2 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P01420(GOT2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P01420(GOT2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The GOT2 antibody targets the mitochondrial enzyme glutamate oxaloacetate transaminase 2 (GOT2), also known as aspartate aminotransferase 2 (AST2). GOT2 is a key player in the malate-aspartate shuttle, facilitating the transfer of reducing equivalents (NADH) across mitochondrial membranes to support cellular energy production. It catalyzes the reversible conversion of aspartate and α-ketoglutarate to oxaloacetate and glutamate, linking amino acid metabolism with the tricarboxylic acid (TCA) cycle. Dysregulation of GOT2 has been implicated in metabolic disorders, cancer progression, and mitochondrial dysfunction.

The GOT2 antibody is widely used in research to investigate protein expression, localization, and function in tissues or cell lines. It serves as a critical tool in Western blotting, immunohistochemistry, and immunofluorescence to study metabolic adaptations in diseases such as hepatocellular carcinoma, renal pathologies, and neurodegenerative conditions. Recent studies highlight its role in tumor microenvironment remodeling, where GOT2 modulates redox balance and nucleotide synthesis. Commercial GOT2 antibodies are typically raised against specific epitopes, with validation in knockout models to ensure specificity. Researchers also explore its potential as a diagnostic or prognostic biomarker, given its altered expression in certain cancers. Understanding GOT2 dynamics through antibody-based assays continues to advance insights into mitochondrial metabolism and therapeutic targeting strategies.